Financings in Brief: Nanogen
This article was originally published in The Gray Sheet
Nanogen: Diagnostics developer plans an initial public offering of up to $40 mil. in common stock. A preliminary prospectus filed with the Securities and Exchange Commission does not specify the anticipated price per share or number of shares to be offered. San Diego-based Nanogen is developing a fully automated, microelectronics-based platform technology for rapid identification and analysis of test samples containing charged molecules, which incorporates a laser-based fluorescence scanner to detect molecular binding. The system has broad commercial applicability in the fields of medical diagnostics, biomedical research, genomics, genetic testing and drug discovery, Nanogen maintains. The firm has a May 1997 joint venture with Becton Dickinson for development of infectious disease diagnostics based on the technology. Separate collaborative agreements signed in December with Hoechst and Elan cover development of drug discovery tools and genomic research applications, respectively.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.